Overview
- The White House, which published its MFN framework Tuesday, said it has voluntary pricing deals with 17 major drugmakers.
- For new drug launches, companies would price U.S. medicines in line with other high‑income countries across all markets, which officials estimate will save $529 billion over 10 years.
- For drugs already on the market, the plan gives state Medicaid programs access to MFN prices that the administration says will save $64.3 billion over a decade.
- The administration said it secured lower prices for GLP‑1 weight‑loss drugs, enabling what it calls a fiscally sustainable expansion of Medicare coverage for anti‑obesity treatment.
- The White House is seeking legislation to lock in the voluntary terms and to require insurers to count MFN direct‑purchase prices toward deductibles and out‑of‑pocket caps.